BAIYUNSHAN PH (00874) has announced that its majority-owned subsidiary, Guangzhou Baiyunshan Tiansin Pharmaceutical Co., Ltd., recently received the Drug Supplement Application Approval Notice from the National Medical Products Administration for Citicoline Sodium Injection in two dosage strengths: 2ml:0.25g and 4ml:0.5g.

This new approval expands the product's available specifications and confirms that the injection has passed the consistency evaluation for generic drug quality and therapeutic equivalence. The regulatory clearance is expected to strengthen the market position of this pharmaceutical offering, enhancing its competitive edge in the sector.